AMENDED CLAIMS
received by the International Bureau on 18 January 2005 : Claims 15-18 and 27-40 are deleted, claims 19-26 are renumbered

or a pharmaceutically acceptable salt or stereoisomer thereof.

14. A pharmaceutical composition that is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.

15. The composition of Claim 14 further comprising a second compound selected from:

1) an estrogen receptor modulator,
2) an androgen receptor modulator,
3) a retinoid receptor modulator,
4) a cytotoxic/cytostatic agent,
5) an antiproliferative agent,
6) a prenyl-protein transferase inhibitor,
7) an HMG-CoA reductase inhibitor,
8) an HIV protease inhibitor,
9) a reverse transcriptase inhibitor,
10) an angiogenesis inhibitor, and
11) a PPAR-γ agonist,
12) a PPAR-δ agonists;
13) an inhibitor of cell proliferation and survival signaling,
14) an agent that interfers with a cell cycle checkpoint, and
15) an apoptosis inducing agent.

16. The composition of Claim 15, wherein the second compound is an angiogenesis inhibitor selected from the group consisting of a tyrosine kinase inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-derived growth factor, an inhibitor of platelet derived growth factor, an MMP inhibitor, an integrin blocker, interferon-α, interleukin-12, pentosan polysulfate, a cyclooxygenase inhibitor, carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-(chloroacetyl-carbonyl)-fumagillol, thalidomide, angiostatin, troponin-1, and an antibody to VEGF.

17. The composition according to Claim 14 further comprising a proteosome inhibitor.

18. The composition according to Claim 14 further comprising a aurora kinase inhibitor.

19. The composition according to Claim 14 further comprising a Raf kinase inhibitor.

20. The composition according to Claim 14 further comprising a serine/threonine kinase inhibitor.

21. The composition according to Claim 14 further comprising an inhibitor of another mitotic kinesin which is not KSP.

22. The composition of Claim 15, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.